United States Patent 7,410,957: Ibandronate Monthly-Dosing Claims, Scope, Expiration, and Generic Risk

U.S. Patent No. 7,410,957 protected the once-monthly oral administration of approximately 150 mg of ibandronic acid for osteoporosis, including tablets containing ibandronic acid sodium salts and specified excipients. The patent covered a dosing method, not ibandronate as a chemical entity. Its term has expired, eliminating current U.S. patent-based blocking risk from this patent. The claims remain relevant for historical Orange Book analysis, Paragraph IV litigation, settlement review, and freedom-to-operate assessments concerning older generic launches.

What does U.S. Patent 7,410,957 protect?

The patent protects a monthly oral osteoporosis regimen using a tablet that delivers approximately 150 mg of ibandronic acid equivalent.

Attribute	Patent 7,410,957
Patent title	Ibandronic acid for the treatment of osteoporosis
Active ingredient	Ibandronic acid, including pharmaceutically acceptable salts
Principal product	Oral ibandronate 150 mg tablet
Therapeutic use	Treatment of osteoporosis
Dosing interval	Once monthly, on a single day
Dosage form	Tablet
Claim type	Method of treatment
Patent owner/assignee	F. Hoffmann-La Roche AG and related Roche entities, as reflected in patent records
U.S. patent	7,410,957
Issue date	August 12, 2008
Earliest priority	2001
U.S. term status	Expired
Historical branded product	Boniva 150 mg tablets

The independent claims divide the protection into two related categories:

Claim 1 requires a first 150 mg-equivalent tablet administered on a single day to commence treatment, followed by once-monthly 150 mg-equivalent tablets.
Claim 6 covers the broader continuation regimen of administering the 150 mg-equivalent tablet once monthly, without expressly requiring the initial treatment dose.

The patent therefore targeted the dosing schedule associated with Boniva's monthly oral tablet rather than the underlying ibandronate molecule.

How are the independent claims structured?

Claim 1: initiation plus continuation

Claim 1 requires all of the following:

A method for treating osteoporosis.
An osteoporosis patient or other subject in need of treatment.
Oral administration.
A tablet dosage form.
An amount of ibandronic acid salt equivalent to approximately 150 mg of ibandronic acid.
An initial dose administered on one day.
Continuation with one tablet administered once monthly on a single day.

The initiation language creates a regimen claim rather than a simple monthly-maintenance claim. A product or treatment protocol that only describes monthly maintenance dosing could present a stronger noninfringement position against claim 1 if it does not practice the claimed commencement step.

Claim 6: monthly administration

Claim 6 is an independent method claim and uses the transitional phrase "consisting of." It requires:

Treatment of osteoporosis.
Oral administration.
A tablet.
Approximately 150 mg of ibandronic acid equivalent.
Administration once monthly on a single day.

Claim 6 does not expressly require the separate initial dose described in claim 1. It is therefore the principal broad monthly-regimen claim in the patent.

The "consisting of" language can limit the claimed method to the recited administration steps and may restrict arguments that additional unrecited treatment steps are part of the claimed method. It does not, by itself, eliminate conventional patient instructions or incidental clinical activity, but it can affect claim construction and infringement analysis.

What are the dependent claims directed to?

Claims 2 through 5 and claims 7 through 10 narrow the active ingredient to ibandronate sodium forms.

Claims	Limitation
2, 7	Sodium salt of ibandronic acid
3, 8	Monosodium, disodium, or trisodium salt
4, 9	Monosodium salt
5, 10	Monosodium salt monohydrate

Claims 11 through 15 depend from claim 2. Claims 16 through 20 depend from claim 7. These claims add tablet excipient limitations.

The listed excipients include:

Lactose
Maize starch
Talc
Stearic acid
Salts of stearic acid
Polyvinylpyrrolidone
Microcrystalline cellulose
Cross-linked polyvinylpyrrolidone
Silicon dioxide
Hydroxypropyl methyl cellulose
Titanium dioxide
Polyethylene glycol 6000

Claims 11 and 16 are open-ended combinations because they require a tablet comprising at least one member of the listed group. Claims 12 through 15 and 17 through 20 separately recite stearic acid, a stearic-acid salt, silicon dioxide, or cross-linked polyvinylpyrrolidone.

These claims are formulation-dependent method claims. They do not broadly claim every ibandronate tablet. They require both the monthly treatment method and the specified formulation limitation.

What is the practical scope of the 150 mg limitation?

The claims measure the dose by the amount of ibandronic acid equivalent, not necessarily by the gross weight of the salt.

A tablet containing a sodium salt of ibandronic acid can weigh more than 150 mg because the salt includes sodium and, for claim 5, water of crystallization. The relevant question is whether the amount of salt corresponds to approximately 150 mg of ibandronic acid active moiety.

The phrase "about 150 mg" creates a range rather than an absolute 150 mg requirement. The permitted range would depend on the intrinsic evidence, prosecution history, specification, and the technical context of the formulation. A generic product labeled as 150 mg ibandronate would have been a direct target for infringement analysis because it is designed to deliver the same active-moiety dose.

What patent landscape surrounded ibandronate and Boniva?

The patent estate included multiple layers, although Patent 7,410,957 was the principal monthly-dose patent.

Patent category	Commercial or legal function
Chemical-entity patents	Protection for ibandronic acid and salts
Pharmaceutical-composition patents	Protection for tablets, excipients, and formulation parameters
Method-of-treatment patents	Protection for monthly oral dosing
Injectable-product patents	Protection for intravenous ibandronate regimens
Regulatory exclusivity	FDA exclusivity associated with the approved product and indication

Patent 7,410,957 was narrower than a compound patent because it required a particular therapeutic use, route, dosage form, dose, and dosing interval. It was commercially important because the monthly regimen differentiated Boniva from daily or weekly bisphosphonate products.

The patent did not claim:

Ibandronic acid as a chemical compound in all uses.
Every dosage strength of ibandronate.
Intravenous administration.
Daily or weekly administration.
Treatment of diseases other than osteoporosis.
Non-tablet oral formulations unless they satisfied the tablet limitation.
A generic formulation independent of the claimed patient-treatment method.

When did Patent 7,410,957 lose exclusivity?

The patent is expired. Public patent and regulatory records place the end of the effective U.S. term in March 2023, with the exact term reflected in the USPTO patent record and historical FDA Orange Book listings.[1,2]

Event	Date
Earliest priority period	2001
PCT/U.S. application period	2002-2003
U.S. patent grant	August 12, 2008
Historical Orange Book relevance	Boniva oral tablets
Patent expiration	March 2023
Current status	Expired

Patent expiration removes the ability to obtain an injunction or damages for post-expiration conduct based solely on this patent. It does not erase historical infringement exposure arising before expiration, subject to applicable limitation periods and case-specific defenses.

Any current U.S. generic manufacturer can rely on the expired status of this patent when assessing monthly ibandronate tablets. Other patents, regulatory requirements, product-specific labeling, and manufacturing rights must still be reviewed separately.

What was the Orange Book status of Patent 7,410,957?

The patent was associated with the oral 150 mg ibandronate product, marketed in the United States as Boniva. The Orange Book historically listed patent information for the approved drug product and provided the framework for ANDA applicants to make Paragraph IV certifications.[2]

The patent's regulatory significance was strongest while it was listed and unexpired. A generic applicant seeking approval before expiration could be required to certify that:

The patent was invalid.
The patent was unenforceable.
The proposed product would not infringe the patent.
The applicant would wait until patent expiration.

A Paragraph IV certification could trigger patent litigation under the Hatch-Waxman Act. Once the listed patent expired, Patent 7,410,957 ceased to create a live Orange Book blocking period.

Which companies challenged the Boniva monthly-dosing patent?

The Boniva product and related ibandronate patents generated ANDA activity and litigation involving generic pharmaceutical companies, including Apotex and other ANDA sponsors reported in public court and regulatory records.

The most visible appellate proceeding was Hoffmann-La Roche Inc. v. Apotex Inc., 748 F.3d 1326 (Fed. Cir. 2014). The case concerned Roche's Boniva-related patent rights and addressed issues relevant to the enforceability and scope of the monthly ibandronate regimen.[3]

Generic applicants typically challenged the patent through one or more of the following theories:

Obviousness based on prior bisphosphonate dosing schedules.
Lack of written description for the monthly 150 mg regimen.
Lack of enablement.
Indefiniteness involving "about 150 mg" or "once monthly."
Noninfringement based on salt form, dose, formulation, or labeling.
Failure of a proposed product to practice the claimed method.

The relevant litigation risk was product-specific. A generic applicant with a label directing once-monthly oral administration of 150 mg ibandronate would face a materially different risk profile from an applicant with a different dose, route, indication, or administration schedule.

What generic launch scenarios existed for ibandronate?

Before expiration, the principal launch scenarios were:

Launch after patent expiration

This was the lowest patent-risk route for a product otherwise eligible for ANDA approval. It avoided infringement based on Patent 7,410,957 but did not resolve other listed patents or regulatory exclusivity.

Launch under a litigation settlement

A generic company could receive a license or agreed entry date from the patent owner. The economic terms could include a delayed launch, supply arrangement, or other restrictions. Public settlement terms are not necessarily complete or commercially detailed.

Launch after a successful Paragraph IV challenge

A generic applicant could launch before patent expiration if it obtained a final favorable judgment, secured a settlement permitting entry, or accepted the risk of an at-risk launch.

Noninfringing design-around

Possible design-around strategies included:

A different dosing interval.
A different strength.
Intravenous rather than oral administration.
A dosage form other than a tablet.
A different indication or label.
A formulation that avoided dependent-claim excipient limitations.

The strength of a design-around depended on the exact product label and actual use. Method-of-treatment claims can be infringed through induced infringement theories where labeling directs physicians or patients to perform the claimed regimen.

How strong was the patent estate?

Patent 7,410,957 had meaningful commercial strength during its term because it aligned closely with the approved Boniva 150 mg monthly tablet. Its strongest features were:

Direct correspondence to the branded product's marketed schedule.
A specific dosage form.
A commercially recognizable 150 mg active-moiety dose.
Dependent claims covering the sodium salt and common tablet excipients.
A method claim that could be asserted against a generic label directing monthly administration.

Its vulnerabilities included:

The claims were method claims rather than compound claims.
The monthly dosing concept could be challenged as obvious based on prior bisphosphonate dosing knowledge.
"About 150 mg" required interpretation.
The dependent excipient claims were narrower and easier to avoid.
Generic applicants could pursue noninfringing indications or dosing instructions.
Expiration ended all prospective exclusivity under this patent.

The estate was therefore commercially strong against an on-label copy of the Boniva monthly tablet while the patent remained enforceable, but less durable than a composition-of-matter patent.

Are biosimilar risks relevant to ibandronate?

No. Ibandronate is a chemically synthesized small-molecule bisphosphonate, not a biologic. The relevant competitors use the ANDA generic-drug pathway, not the biosimilar pathway under the Biologics Price Competition and Innovation Act.

The commercial risks are therefore:

Abbreviated new drug applications.
Paragraph IV certifications.
Generic substitution.
Formulation and manufacturing cost competition.
State substitution laws.
Labeling-based induced-infringement disputes during the patent term.

What manufacturing and formulation barriers remain?

Patent 7,410,957 does not create a continuing manufacturing barrier because it has expired. The technical barriers historically included:

Production of the required ibandronate sodium salt.
Control of the monosodium salt monohydrate form.
Accurate active-moiety equivalence.
Tablet content uniformity.
Stability of the bisphosphonate formulation.
Dissolution and bioequivalence performance.
Compliance with FDA manufacturing controls.
Validated methods for salt, hydrate, and impurity characterization.

The excipient claims could have increased litigation exposure where a generic tablet used the same listed excipients. They did not prevent a manufacturer from using alternative excipient systems after expiration.

How does Patent 7,410,957 compare with compound and formulation patents?

Patent type	Scope	Relative durability
Compound patent	Broad protection for ibandronic acid or a defined salt	Usually strongest
Salt or crystal-form patent	Specific solid form, hydrate, or salt	Intermediate to strong
Formulation patent	Tablet composition or release characteristics	Narrower
Method-of-use patent	Specific osteoporosis regimen	Product-label dependent
Patent 7,410,957	Once-monthly oral 150 mg tablet regimen	Expired and historically important

Patent 7,410,957 was narrower than a compound patent but potentially more directly relevant to the marketed product. Its commercial value came from the match between claim limitations and the Boniva dosing instructions.

What is the current litigation and licensing position?

Patent 7,410,957 is no longer a current U.S. blocking patent. No prospective generic launch should be enjoined solely on the basis of this expired patent.

Historical litigation and settlement agreements may still matter for:

Damages disputes.
Contract interpretation.
Launch-date analysis.
Antitrust or reverse-payment review.
Portfolio diligence.
Valuation of Roche's Boniva franchise.
Assessment of prior generic entry strategies.

The public record supports a distinction between Roche's commercialization arrangements and a patent license. Boniva was commercialized through Roche and commercial partners, including GlaxoSmithKline in the United States, but commercial collaboration should not automatically be treated as a license of Patent 7,410,957.

Key Takeaways

Patent 7,410,957 covered once-monthly oral administration of approximately 150 mg ibandronic acid equivalent for osteoporosis.
Claim 6 was the broadest independent monthly-dosing claim because it did not expressly require the initial commencement dose.
Claims 2-5 and 7-10 narrowed the invention to sodium salts, including monosodium ibandronate monohydrate.
Claims 11-20 added tablet excipient limitations and were narrower formulation-dependent method claims.
The patent was associated with Boniva 150 mg tablets and was historically relevant to ANDA Paragraph IV challenges.
The patent expired in March 2023 and does not create current U.S. blocking exclusivity.
Ibandronate is a small molecule, so generic rather than biosimilar competition is the relevant risk.
Current diligence should focus on other ibandronate patents, FDA approval requirements, manufacturing controls, and any surviving contractual restrictions.

FAQs About U.S. Patent 7,410,957

Does Patent 7,410,957 cover all ibandronate products?

No. It covers a specific osteoporosis treatment regimen using an oral tablet delivering approximately 150 mg of ibandronic acid equivalent once monthly.

Does the patent cover intravenous ibandronate?

No. The asserted claims require oral administration of a tablet.

Does a 150 mg ibandronate generic necessarily infringe the patent?

Not necessarily. Infringement would depend on the product's label, actual use, dosage instructions, salt form, tablet composition, and the patent's legal status. The patent is now expired.

Were the excipient claims composition claims?

No. Claims 11 through 20 are method claims that incorporate tablet-composition limitations. They require administration of a tablet having the claimed active ingredient and excipient limitation.

Can a generic manufacturer rely on the expired patent for current U.S. market entry?

Yes, Patent 7,410,957 no longer provides an enforceable patent barrier. The manufacturer must still address other patents, FDA requirements, bioequivalence, labeling, and manufacturing obligations.

References

United States Patent and Trademark Office. (2008). U.S. Patent No. 7,410,957: Ibandronic acid for the treatment of osteoporosis.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Court of Appeals for the Federal Circuit. (2014). Hoffmann-La Roche Inc. v. Apotex Inc., 748 F.3d 1326.
U.S. Food and Drug Administration. (2005). Boniva (ibandronate sodium) tablets prescribing information.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	02010136	May 10, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	039978	⤷ Start Trial
Argentina	061845	⤷ Start Trial
Austria	376444	⤷ Start Trial
Australia	2003229770	⤷ Start Trial
Australia	2010200438	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,410,957

Summary for Patent: 7,410,957